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patients undergoing balloon angioplasty within 6
months.1 Thrombosis plays an important role. Clinically,
patients with significant thrombus formation encounter
more extensive late lesions,2-4 and therapy to decrease
platelet aggregation decreases rates of restenosis.5 Local
macrophage infiltration during thrombus remodeling
enhances local tissue factor and growth factor levels, which
also promote smooth muscle mitogenesis.6 Other evi-
dence suggests that impaired thrombolysis accelerates pro-
liferative phases of atherosclerotic lesions.7,8 Partial
thrombus formation also alters local flow patterns and
induces shear stress.9 Elements of the thrombotic cascade
impact cellular phenotypes,2,10 thus potentially altering
responses to mechanical damage.11,12
Therapies with antithrombotic moieties or inhibiting
prothrombotic elements limit neointima formation.2,9,13,14
Moreover, clinically significant thrombosis complicates
Clinically significant restenosis occurs in 40% of
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Purpose: Indirect evidence suggests that tissue plasminogen activator (tPA) either limits or does not alter restenosis.
However, tPA enhances tumor invasiveness through matrix remodeling, and several elements of degraded matrix
enhance smooth muscle cell mitogenesis. We use either local adenoviral-mediated overexpression of tPA or systemic
infusion of recombinant tPA combined with mechanical overdilation of rabbit common femoral arteries to evaluate the
impact of tPA on neointima formation.
Methods: Left common femoral arteries of New Zealand white rabbits were transfected in situ either with an adenovi-
ral-construct-expressing tPA or a viral control (adenoviral-construct-expressing β-galactosidase) or nonviral (buffer)
control after balloon angioplasty injury. At 7 and 28 days, left common femoral artery segments were harvested (n =
4 for each group and time point). Vessel segments were examined for intimato-media ratio, smooth muscle cell prolif-
eration, extracellular matrix, and inflammatory response. Thrombus formation was evaluated after 3 days (n = 3 for
each group). In a second experiment, New Zealand white rabbits (n = 3 per group, per time point) underwent mechan-
ical dilation followed by buffer treatment or systemic tPA infusion according to a widely clinically used accelerated infu-
sion protocol. Treated artery segments were harvested after 7 or 28 days and processed for intima-to-media ratio
determination and class-wide histochemical determination of collagenous extracellular matrix and collagen content.
Results: Both rate and degree of neointima formation increase dramatically with overexpression (250%-461% relative to
controls at 7 and 28 days). Substantial early matrix degradation is observed in vessels treated with local overexpression
of tPA, although no increases in local inflammation or in smooth muscle proliferation occur. Late enhancement of
smooth muscle proliferation emerges, consistent with secondary impact of perturbed matrix components. Systemic
infusion of tPA according to clinical protocols also results in early and late enhancement of neointima formation in this
model (34%-52% relative to controls at at 7 and 28 days), with significant early collagenous matrix degradation.
Systemic infusion, although significant, did not attain the degree of neointima formation present with overexpression. 
Conclusion: With some evidence of dose-dependence, tissue plasminogen activator enhances neointima formation after
angioplasty in a rabbit model. Early matrix degradation precedes change in rates of proliferation and underlies this
effect in spite of several antirestenotic actions including decreased thrombus and decreased macrophage recruitment in
this model. (J Vasc Surg 2001;33:821-8.)
15% to 20% of mechanical dilations.15 Thrombolysis with
tissue plasminogen activator (tPA) remains standard of care
for treatment of thrombotic problems, including acute
myocardial infarction and certain types of stroke.16-18
Because thrombosis is so intimately involved both in
restenosis and in the acute arterial occlusion that compli-
cates angioplasty, thrombolysis was expected to improve
outcome for both end points. 4-12,15,19 However, retro-
spective clinical trials of systemic tPA combined with angio-
plasty demonstrate encouraging early improvements in
patency but high rates of late reocclusion.20 Clinical trials
with angioplasty use on an emergency basis after systemic
tPA infusion in a subset of patients (TAMI-7, TIMI-4) may
apply in up to 20% of patients receiving tPA.21,22
On the basis of knockout studies and early in vitro
experiments, several authors have concluded that tPA plays
either no role or a beneficial one in neointima formation,
whereas urokinase-type plasminogen activator (uPA) exerts
proneointimal effects in some models.7,23,24 However,
complex and redundant systems often prove difficult to
evaluate through such strategies, and several elements of
thrombolysis potentially enhance smooth muscle prolifera-
tion and migration. Plasminogen activators directly cleave
some nonfibronectin matrix elements, and plasmin cleaves
fibronectin, laminin, and other extracellular matrix (ECM)
proteins directly.25,26 Plasmin activates elastase and matrix
metalloproteinases.19,27 Degraded matrix presents fewer
architectural barriers and directly enhances migration and
proliferation through specific signaling pathways.28
Degraded collagens are directly mitogenic for smooth
muscle cells.29-31 Plasminogen activators also enhance pro-
liferation and differentiation rates,32 and plasmin induces
proliferation and migration of many cell types.26,33 Fibrin
degradation products, the classical result of plasmin activa-
tion, are also mitogenic for smooth muscle cells.34 Because
tPA is commonly used clinically and exhibits functions that
may, to varying degrees, both limit and enhance neointima
formation in vivo, a study was constructed to evaluate the
impact of both clinical infusion protocols of tPA and sus-
tained local overexpression of tPA on neointima formation
after mechanical overdilation balloon injury.
MATERIAL AND METHODS
Mechanical overdilation and in vivo gene delivery.
Animal experiments followed NIH guidelines. After prein-
duction with ketamine 35 mg/kg and xylazine 4.5 mg/kg,
animals were maintained on isoflurane, and the left super-
ficial femoral artery of each New Zealand white rabbit was
exposed and cannulated. A 2-mm × 2-cm Cordis SAVVY
angioplasty balloon (Cordis, Miami, Fla) was advanced and
inflated to 6 atm for 1 minute twice. An arterial segment
from the inferior epigastric artery to the arteriotomy was
isolated. Contents were aspirated before 15 minutes incu-
bation in phosphate-buffered saline solution (PBS) alone
400 µL, 5 × 109 pfu/mL recombinant adenovirus con-
taining Escherichia coli β-galactosidase gene driven by Rous
sarcoma virus (RSV) promoter (Adv/RSV-βgal, kindly
provided by Dr Michel Perricaudet [Institut Gustave
Roussy at Ville-Juif, France]) 400 µL, or 5 × 109 pfu/mL
recombinant adenovirus expressing tissue plasminogen
activator under the control of RSV (Adv/RSV-tPA; con-
structed and functionally characterized [as previously
described])35 (n as detailed for each experiment below).
Tissue harvesting and determination of intima-to-
media ratios. At 7 or 28 days after mechanical dilation (n =
4 per group for both 7 and 28 day time points), previously
treated vessel segments were excised, and the resulting 1.5-
cm segment was fixed in 10% neutral buffered formalin for
14 to 18 hours and divided into three equal segments.
Vessels from age-matched unmanipulated controls were har-
vested for each time point. Serial cross-sections (4 µm) were
obtained from the proximal face of each segment. Three
random cross sections per vessel (1 per segment) were
obtained by a blinded observer for each processing method
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Fig 1. I/M ratios after local overexpression of tPA. Ratio of intima area–to–media area 7 days (a) or 28 days (b) after balloon dilation
and delivery of PBS, Adv/RSV-βgal, or Adv/RSV-tPA. Values represent mean plus standard error of three randomly selected cross-
sections per vessel. tPA, Tissue plasminogen activator.
a b
detailed below. Routine methods were used for hematoxylin
and eosin staining or Verhoeff elastica staining. A Diagnostic
Instruments, SPOT true-color digital camera (Diagnostics
Instruments, Sterling Heights, Mich) recorded noninterpo-
lated microscopic images. ImagePro Plus analysis system
(Media Cybernetics, Silver Springs, Md) was used to deter-
mine the intima-to-media (I/M) ratio of each on the basis
of area measurements. 
Reproducibility. These experiments were preceded
by pilot experiments (6, 7, and 28 days) that had yielded
similar supportive results, and 7- and 28-day experiments
reported here independently exhibited consistent results.
Furthermore, 7-day time point results were reproduced as
described below to confirm lack of fixation artifact in I/M
results, and rtPA infusion experiments were performed
separately at 7 and 28 days.
Perfusion fixation. Additional animals (n = 4 per
group) underwent mechanical overdilation injury and
gene delivery as described above for PBS, Adv/RSV-βgal,
Adv/RSV-tPA, or normal unmanipulated controls. After 7
days animals underwent standard whole-body perfusion
fixation with treated segments post-fixed in 10% neutral
buffered formalin for 10 to 12 hours. Specimens under-
went I/M determinations as above.
Indexes of smooth muscle proliferation. Sections
from both the 7- and 28-day experiments underwent epi-
tope recovery (HIER 101; Ventana Medical Systems,
Tucson, Ariz). Automated immunohistochemistry was
performed on a TechMate 500 (Ventana Medical
Systems). One section per segment was incubated with
serum and then overnight at room temperature with a pri-
mary monoclonal antibody to proliferating cell nuclear
antigen (PCNA) (PC10; DAKO, Carpenteria, Calif) at a
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dilution of 1:20 or with appropriate controls. Slides were
washed and incubated with a species-specific biotinylated
antimouse immunoglobulin G (Vector Laboratories,
Burlingame, Calif) at 2.25 µg/mL for 45 minutes at room
temperature. Endogenous peroxidase activity was
quenched before incubation with avidin-peroxidase.
Antigenic sites were visualized with diaminobenzidine
with 1% nickel chloride. Sections were blocked and incu-
bated in a primary monoclonal antibody to smooth mus-
cle α-actin (1A4, DAKO) at a dilution of 1:75 and
visualized with species-specific antibody conjugated to
Texas Red. Percent of smooth muscle cells positive for
PCNA was determined via image analysis. 
Evaluation of intra-arterial thrombus formation.
Animals (n = 3 per group) underwent mechanical overdila-
tion and delivery of PBS, Adv/RSV-βgal, or Adv/RSV-
tPA as above 3 days before vessel harvesting. Sections
underwent phosphotungstic acid-hematoxylin (PTAH)
staining to identify cross-sectional thrombus area. Total
percent cross-sectional thrombus was determined by image
analysis as previously reported.35,36 
Evaluation of local extracellular matrix. Elastic lam-
ina and collagenous connective tissue were demonstrated
with a combination of Verhoeff stain and Masson trichrome
stain (sections from the 7-day experiment above). Total col-
lagenous matrix content and elastin content were deter-
mined by image analysis as previously reported.37
Evaluation of local inflammatory cell infiltrate.
Cross sections from the 7-day time point were incubated
with primary monoclonal antibody–to–rabbit macrophage
(clone RAM-11, 1/800 dilution; DAKO), primary mon-
oclonal antibody–to–rabbit CD4 (KEN-4; Spring Valley
Labs, Woodbine, Md), or subjected to cellular chloroac-
Fig 2. Representative photomicrographs. Representative low (original magnification × 10) and high (original magnification × 100) mag-
nification photographs of sections obtained 7 days after mechanical overdilation and delivery of (a) PBS, (b) Adv/RSV-βgal, or 
(c) Adv/RSV-tPA. Sections were stained with combination of Verhoeff elastica stain and Masson trichrome stain.
etate esterase staining to visualize neutrophilic granulo-
cytes as previously reported.36-38 The number of positive
cells per cross-section was determined.
Systemic infusion of tPA. New Zealand white rabbits
(n = 3 per group, per time point) underwent mechanical
dilation as above followed by control buffer treatment
(without tPA added) or systemic tPA infusion (rtPA;
Genentech, S. San Francisco, Calif) according to the
widely clinically used accelerated infusion protocol (0.15
mg/kg bolus of tPA given intravenously via ear vein, fol-
lowed by infusion of 0.75 mg/kg over 30 minutes, then
by 0.5 mg/kg over 60 minutes). Treated artery segments
were harvested after 7 or 28 days and processed as before
for I/M ratio determination and class-wide histochemical
determination of collagen and elastin content.
RESULTS 
I/M ratios after overexpression of tPA. Local over-
expression of tPA enhances degree of neointima formation
after mechanical overdilation to 250% to 344% of balloon-
injured controls after 28 days (P < .01 relative to nonviral
and viral controls, which were comparable to one another,
P > .05) (Fig 1, b). Neointima with tPA increased to 310%
to 461% of control values after only 7 days in these same
experiments (P < .01 relative to nonviral and viral con-
trols, whereas viral controls significantly declined relative
to nonviral controls, P < .05) (Fig 1, a). An additional
experiment was performed for each group at 7 days with
perfusion fixation to confirm that results were not biased
by selection of fixation method. No group exhibited sig-
nificant deviation from the results presented above, and
Adv/RSV-tPA exhibited comparable statistically signifi-
cant enhancement of neointima formation relative to both
nonviral (P = .0001) and viral controls (P = .001). Fig 2
presents representative photomicrographs depicting the
predominantly cellular neointima observed at 7 days.
Smooth muscle cell proliferation after overexpres-
sion of tPA. Vessels treated with the Adv/RSV-tPA con-
struct exhibited rates of smooth muscle proliferation that
were not statistically significantly different from nonviral
controls at 7 days (P > .05) (Fig 3, a). In contrast,
decreased rates were observed at this time point in viral
controls relative to Adv/RSV-tPA (P < .01) and buffer
controls (P < .05), possibly because of enhanced cell
death, as supported by qualitative observation of increased
local debris and increases in granulocyte infiltration. At 28
days after injury, Adv/RSV-tPA vessels exhibited nearly
fourfold elevated rates of smooth muscle proliferation rel-
ative to both viral and nonviral controls (P < .01 each),
which were comparable to one another (P > .05) (Fig 3,
b). Because no increase in early rate of proliferation
occurred, enhanced migration had likely led to the
increased neointima formation, either through local
thrombosis or through local matrix remodeling.
Intra-arterial thrombus formation after local over-
expression of tPA. As anticipated from previous work,35
local overexpression of tPA leads to statistically significant
decreases in intraarterial thrombus formation relative to
both viral and nonviral controls (P < .05 for each) (Fig 4).
Viral controls encounter statistically significant increases in
thrombus bulk relative to nonviral controls (P < .05).
Enhancement in 7-day neointima formation with local
overexpression of tPA thus does not occur through any
acceleration of thrombus bulk because animals treated
with tPA encounter significant declines in local thrombus
relative to controls. 
Evaluation of vessel wall matrix after overexpression
of tPA. Because proliferation had not increased with
Adv/RSV-tPA relative to controls at 7 days but I/M had
significantly increased at this time, enhanced rates of inva-
sion of smooth muscle into the intima had most likely
occurred in this group. Because extracellular matrix poses a
primary architectural barrier to migration and proliferation,
and because tPA and plasmin degrade matrix elements,
quantitation of elastin and collagen was undertaken at 7
days, with results summarized in Table I. Ad/RSV-tPA
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Fig 3. Smooth muscle proliferation after local overexpression of tPA. Indexes of proliferating smooth muscle cells at 7 (a) or 28 (b) days
after balloon dilation and delivery of PBS, Adv/RSV-βgal, or Adv/RSV-tPA. tPA, Tissue plasminogen activator.
a b
elastin content decreased to 24% of nonviral controls, and
collagen decreased to 43% of nonviral controls. Thus signif-
icantly enhanced matrix degradation occurred in the
Adv/RSV-tPA group relative to nonviral controls (P < .01
for each parameter). Although Adv/RSV-tPA also pro-
duced statistically significant elastin and collagenous extra-
cellular matrix degradation relative to viral controls (P < .01
for each parameter), the viral controls exhibited significant
decreases in elastin (P < .01) but not collagen relative to
nonviral controls (P > .05). Before direct contributions of
tPA could be demonstrated, it remained to be confirmed
that decreased matrix was not due to increases in local
inflammation, with subsequent matrix degradation. Given
the potential role of macrophage stimulation of SMC pro-
liferation, these evaluations become essential to demon-
strate tPA-specific effects. Although all effects demonstrated
to this point were significant relative to viral controls, each
could potentially be explained by enhanced inflammatory
response to tPA, rather than to viral antigens. 
Local inflammatory responses after overexpression
of tPA. Infiltration of granulocytes, CD4+ T cells, and
macrophages was evaluated at 7 days, with the results pre-
sented in Table II. Adv/RSV-tPA vessels did not exhibit any
statistically significant alterations in granulocyte infiltration
relative to nonviral controls (P > .05). Interestingly, viral
controls revealed statistically significant increased infiltra-
tion of potentially elastase-degrading granulocytes relative
to both Adv/RSV-tPA (P < .05) and nonviral controls (P <
.05); decreased elastin content in the viral control relative to
nonviral control thus may be caused by inflammation to 
β-gal antigen (with some uncertain contribution of viral
antigens, because Adv/RSV-tPA remains comparable to
nonviral controls). No statistically significant differences in
number of CD4+ T-cells occurred between groups (P > .05
for all comparisons). Macrophage infiltration was not
increased in the viral control relative to nonviral controls 
(P > .05). Interestingly, significant decreases in local macro-
phage infiltration occurred with Adv/RSV-tPA treatment
relative to both viral and nonviral controls (P < .01 each).
Overall, no increases in local granulocyte, CD4+ T cell, or
macrophage infiltration occurred with Adv/RSV-tPA. 
I/M ratios after systemic infusion of tPA. Although
local overexpression of tPA had encountered rapid neoin-
tima formation caused by matrix remodeling, these effects
may be due to relatively high levels of expression accom-
plished locally. A separate experiment was thus performed
to investigate the impact of systemic infusion of recombi-
nant tPA as used routinely for management of acute
myocardial infarction. I/M ratios were determined as more
than 28 days after balloon injury (Fig 5, b). Statistically sig-
nificant 34% increases in neointima formation occurred in
the systemic tPA group relative to controls (P < .05). I/M
ratios were also determined in a 7-day experiment (Fig 5,
a). Treatment with systemic infusion of tPA yielded a 52%
increase in neointima formation relative to controls (P <
.05) after only 7 days. Thus, although systemic treatment
did not exhibit the 2.5- to 4.6-fold increases encountered
with local overexpression, rtPA does enhance early and late
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neointima formation in this model. Because potential
mechanisms underlying this progression had been charac-
terized with local overexpression of tPA, it remained to be
confirmed that early matrix degradation again occurred at
the tPA levels accomplished with systemic infusion.
Matrix remodeling after systemic infusion of tPA.
Extent of class-wide collagenous matrix and elastin are
summarized in Table III. Statistically significant reduc-
tions in collagenous matrix were again observed with rtPA
treatment relative to controls (P < .05). However, trend-
ing decreases in elastin content were not significant in this
Fig 4. Intra-arterial thrombus formation after local overexpres-
sion of tPA. Cross-sectional percent thrombus formation 3 days
after balloon dilation and delivery of PBS, Adv/RSV-βgal, or
Adv/RSV-tPA. tPA, Tissue plasminogen activator. 
Table II. Number of neutrophilic granulocytes, RAM-
11–positive rabbit macrophages, or CD4+ T cells per
cross-section 7 days after balloon dilation and delivery 
of PBS, Adv/RSV-βgal, or Adv/RSV-tPA
Esterase RAM-11 CD4+
Buffer 33.00 ± 6.33 5.39 ± 1.23 27.31 ± 4.56
βgal 53.58 ± 8.60 5.83 ± 0.97 18.38 ± 2.85
tPA 31.67 ± 5.48 0.17 ± 0.12 13.91 ± 3.15
Table I. Extracellular matrix: cross-sectional elastin and
collagenous extracellular matrix content 7 days after injury
and delivery of PBS, Adv/RSV-βgal, or Adv/RSV-tPA
Elastin Collagen
Buffer 4.60 ± 0.56 10.20 ± 0.62
βgal 2.91 ± 0.27 10.36 ± 1.08
tPA 1.11 ± 0.29 4.35 ± 0.96
experiment (P > .05). Although the matrix remodeling
was not as severe as with local overexpression of tPA, sys-
temic tPA infusion did result in significant local matrix
degradation relative to controls.
DISCUSSION
In this work we demonstrate that tissue plasminogen
activator both can and, after clinical infusion protocols,
does enhance neointima formation after balloon injury in
rabbit common femoral arteries. Potential contributions
to early and late tPA-mediated enhancement of neointima
are characterized through adenoviral-mediated local over-
expression of tPA, and overall effects are confirmed with
systemic infusion of tPA according to the routinely used
protocol for acute myocardial infarction. Local overex-
pression of tPA led to 2.5- to 4.60-fold increases in neoin-
tima formation relative to controls at both 28-day and
7-day time points.
Surprisingly, early (7-day) rates of proliferation with
Adv/RSV-tPA were not statistically different from nonvi-
ral controls, although degree of neointima was elevated at
this same time point. We confirmed assay validity through
evaluation of proliferation rates at 28 days. In spite of
roughly threefold increases degree of neointima at 28 days
relative to controls, animals treated with Adv/RSV-tPA
still exhibit substantially increased smooth muscle prolifer-
ation and may be found to have further worsened out-
come at later time points. Results for Adv/RSV-tPA could
be due to late stimulation of smooth muscle mitogenesis
or to prevention of the declining proliferation that occurs
in control groups. The relative contribution of each can-
not be ascertained in this study, but both are likely to be
present because Adv/RSV-tPA vessels exhibited nearly
twofold higher indexes of smooth muscle proliferation at
28 days than at 7 days, whereas controls decreased to
roughly half of 7-day values. Regardless, these two analy-
ses suggest that, although enhanced rates of smooth mus-
cle proliferation may contribute to the late outcome in the
Adv/RSV-tPA group, early increases in neointima are pri-
marily due to other factors.
Because thrombus formation enhances both neointima
formation and clinical restenosis after angioplasty, degree
of intraarterial thrombus formation was quantitated. As
expected, local overexpression of tPA results in decreased
local thrombus bulk. The increases in 7-day neointima with
Adv/RSV-tPA thus did not reflect secondary effects of
increased thrombosis or organizing thrombus. Indeed,
decreased local thrombus bulk represents a potent anti-
neointimal impetus. Other proneointimal contributions of
tPA must thus become more important in this model. 
Significant early collagen and elastin degradation
occurred with Adv/RSV-tPA relative to both controls.
Given the inhibitory effect of normal matrix on smooth
muscle proliferation and the stimulatory effect of degraded
matrix components, tPA-mediated enhancements in local
matrix degradation likely underlie the enhanced neointima
observed. However, before a tPA-specific role can be con-
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Fig 5. I/M ratios after systemic infusion of tPA. Ratio of intima area–to–media area 7 days (a) or 28 days (b) after mechanical overdi-
lation and delivery of PBS, or systemic infusion of tPA as described.
Table III. Extracellular matrix after systemic infusion of
tPA: cross-sectional elastin and collagenous extracellular
matrix content 7 days after mechanical overdilation and
delivery of PBS or systemic infusion of tPA as described
Elastin Collagen
Buffer 4.48 ± 0.73 14.54 ± 1.49
rtPA 3.90 ± 0.91 10.01 ± 1.30
a b
firmed, the possibility that matrix remodeling occurred as
a result of local inflammation had to be excluded.
No increases in local neutrophil or CD4+ T-cell infiltrate
were observed in Adv/RSV-tPA animals relative to controls.
Interestingly, significant decreases in local macrophage infil-
tration occurred with Adv/RSV-tPA treatment relative to
both controls. Although the mechanism underlying this
reduction cannot be ascertained from this experiment, the
observation that macrophages, which classically promote
neointimal proliferation, are decreased in spite of the dra-
matic increase in I/M ratio provides additional insight into
the potential impact of matrix remodeling on these
processes. Decreased local macrophage infiltration, which
should decrease extent of subsequent neointima formation,
was again insufficient to overcome the prorestenotic impe-
tus of vascular matrix remodeling.
Protocols for systemic infusion of tPA have become
standard of care for a number of clinical thrombotic prob-
lems that taken together represent the leading cause of
death in Western nations. However, this work demon-
strates that this protocol significantly enhances both early
and late neointima formation in a rabbit model. As occurs
with local tPA overexpression, some significant early
matrix degradation also occurred with this protocol and
likely underlies the observed effects. Future experiments
to further characterize the importance of these observa-
tions must be undertaken in this model system and others,
including direct modeling of restenosis itself. Encour-
agingly, systemic infusion did not encounter the same rate
of accelerated neointima formation that occurred with
local overexpression of tPA. Thus some evidence for dose
dependence is present in these studies, and a threshold
below which these proneointimal effects do not occur may
be found. If similar effects are observed in human beings
and nonhuman primates, then reevaluation of alternate
dosages may permit achievement of both effective throm-
bolysis and improved long-term patency. 
Overall, this work suggests that local overexpression of
tPA may alter vascular remodeling and substantially
enhance subsequent neointima formation and restenosis,
contrary to some interpretations of recent reports based on
tPA knockout studies.7,23,24 Furthermore, systemic infusion
of tPA alters matrix proteolysis and subsequent neointimal
proliferation in injured vessels. These results are consistent
with the clinical observation that systemic tPA combined
with angioplasty produces early improvements in patency
but high rates of late reocclusion.20 Given the results of
these experiments, impact of this therapy on these and
related processes must be closely scrutinized. The potential
significance of the studies presented here goes further,
though. In spite of decreased thrombus bulk and decreased
macrophage infiltration, matrix remodeling significantly
increases neointima formation. Furthermore, these in vivo
experiments complement observations made by Koyama et
al,29 Ross,31 and others30 that normal matrix elements may
represent a nonpermissive environment for smooth muscle
proliferation, whereas degradation of collagen itself may
provide at least a promigratory stimulus. This work, taken
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with a growing body of evidence from other areas, thus
emphasizes the potential importance of vascular extracellu-
lar matrix as a growth regulator in injured vessels.
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